Non-lesional Atopic Dermatitis Skin Is Characterized by Broad Terminal Differentiation Defects and Variable Immune Abnormalities

Mayte Suárez‐Fariñas(Rockefeller University), Emma Guttman‐Yassky(Icahn School of Medicine at Mount Sinai)

Journal of Allergy and Clinical Immunology

March 16, 2011

10.1016/j.jaci.2010.12.1124

Cited by 457

Related Papers

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis

|New England Journal of Medicine|2016|2k

A molecular single-cell lung atlas of lethal COVID-19

|Nature|2021|735

Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*

|British Journal of Dermatology|2020|590

Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials

|The Lancet|2021|538

Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis

|JAMA Dermatology|2019|505